IP Library Granted Patent US 9,272,104
Granted Patent B2
US 9,272,104 · App. 12/293,972 · Granted Mar 1, 2016

Nasal delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,104
App. No.
12/293,972
Granted
Mar 1, 2016
Kind
B2
Abstract

A delivery device for and method of delivering a dose of substance for systemic uptake to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit for insertion into a nasal cavity of a subject and comprising an outlet unit which includes at least one nozzle for delivering substance for systemic uptake substantially only to surfaces in one or both of the anterior region and an anterior section of the posterior region of the nasal cavity of the subject; and a substance supply unit which is operable to deliver a dose of substance to the at least one nozzle.

Claims (23)

1. A delivery device for delivering one or more substances to a nasal cavity of a subject for systemic uptake, the delivery device comprising:

a nosepiece for insertion into the nasal cavity of the subject, the nosepiece including an outlet unit having a first nozzle; and

a substance supply unit operable to deliver a first substance to the first nozzle;

wherein the first nozzle is configured to deliver the first substance to: (i) either or both of a first region and/or a second region, or (ii) substantially only to the first region; and

wherein the first region is an anterior region of the nasal cavity of the subject, the anterior region being anterior to a nasal valve of the subject, and the second region is an anterior section of a posterior region of the nasal cavity of the subject, the anterior section of the posterior region being posterior of the nasal valve of the subject; and

a second nozzle configured to deliver a second substance to a third region, wherein the third region is a posterior section of the posterior region of the nasal cavity of the subject, the posterior section of the posterior region being posterior to the anterior section of the posterior region.

2. The delivery device of claim 1 , wherein the first nozzle is further configured to deliver the first substance to a middle-third portion of the anterior section of the posterior region.

3. The delivery device of claim 1 , wherein the substance supply unit is breath actuated by either oral exhalation of the subject or by nasal exhalation of the subject.

4. The delivery device of claim 1 , wherein the substance supply unit is manually actuated.

5. The delivery device of claim 1 , wherein the first nozzle is configured to deliver an aerosol spray, wherein the aerosol spray is a liquid aerosol or a powder aerosol.

6. The delivery device of claim 1 , wherein the first nozzle is configured to deliver a liquid jet or a powder jet.

7. The delivery device of claim 1 , wherein the first nozzle is configured to deliver the first substance substantially laterally with respect to a base portion of the nosepiece.

8. The delivery device of claim 1 , further comprising a mouthpiece through which the subject in use exhales to cause closure of an oropharyngeal velum of the subject.

9. The delivery device of claim 1 , wherein the outlet unit further comprises a posterior nosepiece member configured to obstruct the nasal cavity at a position therealong such that substantially all of the first substance delivered from the first nozzle is delivered to a region of the nasal cavity of the subject that is anterior of the posterior nosepiece member.

10. The delivery device of claim 9 , wherein the posterior nosepiece member is configured to close the nasal valve.

11. The delivery device of claim 9 , wherein the posterior nosepiece member comprises one of (i) an expandable member, (ii) a resilient member that self-expands upon insertion into the nasal cavity of the subject to obstruct and partition the nasal cavity of the subject when expanded, or (iii) an inflatable member configured to be inflated subsequent to insertion into the nasal cavity of the subject to obstruct and partition the nasal cavity of the subject when inflated.

12. The delivery device of claim 9 , further comprising a mouthpiece through which the subject in use exhales to cause closure of an oropharyngeal velum of the subject, wherein the mouthpiece is fluidly connected to the posterior nosepiece member, whereby in use exhaled air from an exhalation breath of the subject inflates the posterior nosepiece member.

13. The delivery device of claim 9 , wherein the outlet unit further includes an anterior nosepiece member configured to obstruct an opening of the nasal cavity of the subject anterior to the nasal valve.

14. The delivery device of claim 1 , wherein the outlet unit further includes an anterior nosepiece member configured to obstruct an opening of the nasal cavity of the subject anterior to the nasal valve.

15. The delivery device of claim 1 , wherein the outlet unit further comprises a posterior nosepiece member configured to obstruct the nasal cavity at a position therealong, such that (i) substantially all of a dose of the first substance delivered from the first nozzle is delivered to a region of the nasal cavity of the subject anterior of the posterior nosepiece member, and (ii) substantially all of the dose of the second substance delivered from the second nozzle is delivered to a region of the nasal cavity of the subject posterior of the posterior nosepiece member.

16. The delivery device of claim 15 , wherein the posterior nosepiece member comprises one of (i) an expandable member, (ii) a resilient member that self-expands upon insertion into the nasal cavity of the subject to obstruct and partition the nasal cavity of the subject when expanded, or (iii) an inflatable member configured to be inflated subsequent to insertion into the nasal cavity of the subject to obstruct and partition the nasal cavity of the subject when inflated.

17. The delivery device of claim 1 , wherein the first substance and the second substance are different substances.

18. The delivery device of claim 1 , wherein the first substance and the second substance are the same substance.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded May 21, 2025
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: OPTINOSE INC.
Reel/Frame 071547/0979 →
CHANGE OF ADDRESS Recorded Jan 7, 2025
From: OPTINOSE, INC.
To: OPTINOSE, INC.
Reel/Frame 069834/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: OPTINOSE AS
To: OPTINOSE INC
Reel/Frame 061546/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: DJUPESLAND, PER GISLE
To: OPTINOSE AS
Reel/Frame 053813/0224 →
RELEASE OF SECURITY AGREEMENT RECORDED AT REEL 044976 FRAME 0505 Recorded Sep 13, 2019
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: OPTINOSE AS
Reel/Frame 050371/0894 →
SECURITY INTEREST Recorded Sep 13, 2019
From: OPTINOSE AS
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 050371/0913 →
SECURITY INTEREST Recorded Dec 29, 2017
From: OPTINOSE AS
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 044976/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2017
From: DJUPESLAND, PER GISLE
To: OPTINOSE AS
Reel/Frame 042702/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2009
From: DJUPESLAND, PER GISLE
To: OPTINOSE AS
Reel/Frame 022721/0342 →